Guangzhou huajin Pharmaceutical has raised over 10 million USD in pre-Series B round to promote the global development of the world’s first tumor-targeting oncolytic bacteria drug.
May 23,2022, Guangzhou Sinogen Pharmaceutical recently completed pre-Series B round of financing worth over 10 million US dollars. This round was led by Winzac Capital(Chinese:稳正资产), followed by Classmate Village Venture Capital(Chinese:同学村创投), Cher Ami Investment(Chinese:谢诺投资) and Sinowisdom Fund(Chinese:华睿基金).This round of financing will be mainly used to accelerate the clinical trials of SGN1 which is world’s first tumor-targeting drug based on Amino Acid metabolism, and promote the development of new products.
huajin Pharmaceutical is a biotechnology company committed to the development and production of innovative biological oncology drugs to meet the global demand for the treatment of a broad malignant tumors. At the beginning of its establishment, the company has successively obtained multiple rounds of investment from well-known institutions such as Share Capital(Chinese:分享投资), CICC Capital(Chinese:中金启德基金) and Winzac Capital(Chinese:稳正资产). Up to now, the accumulated amount of each round of financing completed by the company has reached tens of millions of US dollars.
SGN1 independently developed by huajin pharmaceutical is the world's first genetic engineering biological product that has entered the clinical trial stage and can accurately and rapidly dissolve tumors. Attenuated Salmonella have been used as methionine hydrolase carriers to deprive essential amino acids required for tumor growth, thus killing tumor and preventing tumor proliferation. At present, 18 international PCT (Patent Cooperation Treaty) patent application for SGN1 has legal effect. So far, it has shown outstanding efficacy and safety in animal experiments and investigator-sponsored clinical studies in multiple malignant tumors including Liver cancer, lung cancer, sarcoma, melanoma, nasopharyngeal carcinoma and cervical cancer.
started phase i/iia clinical trials of SGN1 in multiple clinical trial centers in the US for both intravenous administration and intratumoral administration.This two clinical trials recruited patients with liver cancer, lung cancer, head and neck cancer, melanoma, sarcoma and other advanced malignant solid tumors huajin is also planning to start multicenter clinical trials in different countries and regions such as Mainland China, Taiwan, South Korea, Australia etc.. Meanwhile, huajin is going to submit more than 2 Orphan Drug Designation of SGN1 in treating multiple malignant tumor indications by the end of year.
Dr. Allan Zijian Zhao, Chairman&CEO said.
“We would like to express our gratitude to all the investors for your trust and support, especially Winzac Capital(稳正基金) who lead this round of financing which fully demonstrates its insight into original technologies and its strength and responsibility as an elite investment institution. This round of financing funds will be mainly used to accelerate the clinical trials of SGN1 in multiple advanced malignant solid tumors and promote the development of new products of the company. SGN1 is the world's first tumor-targeted genetically engineered biological product. It can be administered through both intratumoral injection and intravenous injection to treat non superficial tumors and metastatic tumors in vivo. SGN1 will open up a new therapeutic field of tumor-targeting amino acid metabolic pathway regulation therapy and bring new solutions to the treatment of malignant tumors.”
